Skip to main content
Top
Published in: Diabetologia 10/2015

01-10-2015 | Article

Influence of endogenous NEFA on beta cell function in humans

Authors: Eleni Rebelos, Marta Seghieri, Andrea Natali, Beverly Balkau, Alain Golay, Pier Marco Piatti, Nebojsa M. Lalic, Markku Laakso, Andrea Mari, Ele Ferrannini

Published in: Diabetologia | Issue 10/2015

Login to get access

Abstract

Aims/hypothesis

It is a commonly held view that chronically elevated NEFA levels adversely affect insulin secretion and insulin action (lipotoxicity). However, the effect of NEFA on beta cell function has only been explored using acute NEFA elevations. Our aim was to analyse the relationship between endogenous NEFA levels and beta cell function.

Methods

In 1,267 individuals followed-up for 3 years, we measured insulin sensitivity (by clamp) and beta cell function (by C-peptide modelling during OGTT and as the acute insulin response [AIR] to IVGTT).

Results

At baseline, both fasting and insulin-suppressed NEFA levels were higher across glucose tolerance groups, while insulin sensitivity was lower, insulin output was higher, and beta cell glucose sensitivity and AIR were lower (all p < 0.0001). In multiple logistic analyses adjusting for age, BMI, WHR and glucose tolerance, both fasting and insulin-suppressed NEFA levels were inversely related to insulin sensitivity, as expected (both p < 0.0001). Furthermore, after adjusting for insulin sensitivity, insulin-suppressed NEFA were positively associated with total insulin output (p = 0.0042). In contrast, neither fasting nor insulin-suppressed NEFA were related to beta cell glucose sensitivity or AIR. At follow-up, worsening of glucose tolerance (n = 126) was predicted by lower insulin and beta cell glucose sensitivity. In this model, baseline NEFA were not significant predictors of progression.

Conclusions/interpretation

In the non-diabetic state and in subjects with impaired glucose tolerance, circulating endogenous NEFA are not independently associated measures of beta cell function, and do not predict deterioration of glucose tolerance. Thus, in the Relationship Between Insulin Sensitivity and Cardiovascular Disease (RISC) cohort there is no evidence for beta cell lipotoxicity of endogenous total NEFA concentrations.
Literature
1.
go back to reference Ferrannini E, Camastra S, Coppack SW, Fliser D, Golay A, Mitrakou A (1997) Insulin action and non-esterified fatty acids. The European Group for the Study of Insulin Resistance (EGIR). Proc Nutr Soc 56:753–761CrossRefPubMed Ferrannini E, Camastra S, Coppack SW, Fliser D, Golay A, Mitrakou A (1997) Insulin action and non-esterified fatty acids. The European Group for the Study of Insulin Resistance (EGIR). Proc Nutr Soc 56:753–761CrossRefPubMed
2.
go back to reference Lafontan M, Langin D (2009) Lipolysis and lipid mobilization in human adipose tissue. Prog Lipid Res 48:275–797CrossRefPubMed Lafontan M, Langin D (2009) Lipolysis and lipid mobilization in human adipose tissue. Prog Lipid Res 48:275–797CrossRefPubMed
3.
go back to reference Randle PJ, Garland PB, Hales CN, Newsholme EA (1963) The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1:785–789CrossRefPubMed Randle PJ, Garland PB, Hales CN, Newsholme EA (1963) The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1:785–789CrossRefPubMed
5.
go back to reference Unger RH (1995) Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 44:863–870CrossRefPubMed Unger RH (1995) Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 44:863–870CrossRefPubMed
6.
go back to reference Briaud I, Harmon JS, Kelpe CL, Segu VB, Poitout V (2001) Lipotoxicity of the pancreatic beta-cell is associated with glucose-dependent esterification of fatty acids into neutral lipids. Diabetes 50:315–321PubMedCentralCrossRefPubMed Briaud I, Harmon JS, Kelpe CL, Segu VB, Poitout V (2001) Lipotoxicity of the pancreatic beta-cell is associated with glucose-dependent esterification of fatty acids into neutral lipids. Diabetes 50:315–321PubMedCentralCrossRefPubMed
7.
go back to reference McGarry JD (2002) Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 51:7–18CrossRefPubMed McGarry JD (2002) Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 51:7–18CrossRefPubMed
8.
go back to reference Warnotte C, Gilon P, Nenquin M, Henquin JC (1994) Mechanisms of the stimulation of insulin release by saturated fatty acids. A study of palmitate effects in mouse beta-cells. Diabetes 43:703–711CrossRefPubMed Warnotte C, Gilon P, Nenquin M, Henquin JC (1994) Mechanisms of the stimulation of insulin release by saturated fatty acids. A study of palmitate effects in mouse beta-cells. Diabetes 43:703–711CrossRefPubMed
9.
go back to reference Zhou YP, Grill VE (1994) Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. J Clin Invest 93:870–876PubMedCentralCrossRefPubMed Zhou YP, Grill VE (1994) Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. J Clin Invest 93:870–876PubMedCentralCrossRefPubMed
10.
go back to reference Elks ML (1993) Chronic perifusion of rat islets with palmitate suppresses glucose-stimulated insulin release. Endocrinology 133:208–214PubMed Elks ML (1993) Chronic perifusion of rat islets with palmitate suppresses glucose-stimulated insulin release. Endocrinology 133:208–214PubMed
11.
go back to reference Stein DT, Esser V, Stevenson BE et al (1996) Essentiality of circulating fatty acids for glucose-stimulated insulin secretion in the fasted rat. J Clin Invest 97:2728–2735PubMedCentralCrossRefPubMed Stein DT, Esser V, Stevenson BE et al (1996) Essentiality of circulating fatty acids for glucose-stimulated insulin secretion in the fasted rat. J Clin Invest 97:2728–2735PubMedCentralCrossRefPubMed
12.
go back to reference Sako Y, Grill VE (1990) A 48-hour lipid infusion in the rat time-dependently inhibits glucose-induced insulin secretion and B cell oxidation through a process likely coupled to fatty acid oxidation. Endocrinology 127:1580–1589CrossRefPubMed Sako Y, Grill VE (1990) A 48-hour lipid infusion in the rat time-dependently inhibits glucose-induced insulin secretion and B cell oxidation through a process likely coupled to fatty acid oxidation. Endocrinology 127:1580–1589CrossRefPubMed
13.
go back to reference Mason TM, Goh T, Tchipashvili V et al (1999) Prolonged elevation of plasma free fatty acids desensitizes the insulin secretory response to glucose in vivo in rats. Diabetes 48:524–530CrossRefPubMed Mason TM, Goh T, Tchipashvili V et al (1999) Prolonged elevation of plasma free fatty acids desensitizes the insulin secretory response to glucose in vivo in rats. Diabetes 48:524–530CrossRefPubMed
14.
go back to reference Boden G, Chen X, Rosner J, Barton M (1995) Effects of a 48-h fat infusion on insulin secretion and glucose utilization. Diabetes 44:1239–1242CrossRefPubMed Boden G, Chen X, Rosner J, Barton M (1995) Effects of a 48-h fat infusion on insulin secretion and glucose utilization. Diabetes 44:1239–1242CrossRefPubMed
15.
go back to reference Boden G, Chen X (1999) Effects of fatty acids and ketone bodies on basal insulin secretion in type 2 diabetes. Diabetes 48:577–583CrossRefPubMed Boden G, Chen X (1999) Effects of fatty acids and ketone bodies on basal insulin secretion in type 2 diabetes. Diabetes 48:577–583CrossRefPubMed
16.
go back to reference Carpentier A, Mittelman SD, Lamarche B, Bergman RN, Giacca A, Lewis GF (1999) Acute enhancement of insulin secretion by FFA in humans is lost with prolonged FFA elevation. Am J Physiol 276:E1055–E1066PubMed Carpentier A, Mittelman SD, Lamarche B, Bergman RN, Giacca A, Lewis GF (1999) Acute enhancement of insulin secretion by FFA in humans is lost with prolonged FFA elevation. Am J Physiol 276:E1055–E1066PubMed
17.
go back to reference Carpentier A, Mittelman SD, Bergman RN, Giacca A, Lewis GF (2000) Prolonged elevation of plasma free fatty acids impairs pancreatic beta-cell function in obese nondiabetic humans but not in individuals with type 2 diabetes. Diabetes 49:399–408CrossRefPubMed Carpentier A, Mittelman SD, Bergman RN, Giacca A, Lewis GF (2000) Prolonged elevation of plasma free fatty acids impairs pancreatic beta-cell function in obese nondiabetic humans but not in individuals with type 2 diabetes. Diabetes 49:399–408CrossRefPubMed
18.
go back to reference Kashyap S, Belfort R, Gastaldelli A et al (2003) A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 52:2461–2474CrossRefPubMed Kashyap S, Belfort R, Gastaldelli A et al (2003) A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 52:2461–2474CrossRefPubMed
19.
go back to reference Paolisso G, Tataranni PA, Foley JE, Bogardus C, Howard BV, Ravussin E (1995) A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Diabetologia 38:1213–1217CrossRefPubMed Paolisso G, Tataranni PA, Foley JE, Bogardus C, Howard BV, Ravussin E (1995) A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Diabetologia 38:1213–1217CrossRefPubMed
20.
go back to reference Stefan N, Stumvoll M, Bogardus C, Tataranni PA (2003) Elevated plasma nonesterified fatty acids are associated with deterioration of acute insulin response in IGT but not NGT. Am J Physiol Endocrinol Metab 284:E1156–E1161CrossRefPubMed Stefan N, Stumvoll M, Bogardus C, Tataranni PA (2003) Elevated plasma nonesterified fatty acids are associated with deterioration of acute insulin response in IGT but not NGT. Am J Physiol Endocrinol Metab 284:E1156–E1161CrossRefPubMed
21.
go back to reference Hills SA, Balkau B, Coppack SW et al (2004) The EGIR-RISC STUDY (The European group for the study of insulin resistance: relationship between insulin sensitivity and cardiovascular disease risk): I. Methodology and objectives. Diabetologia 47:566–570CrossRefPubMed Hills SA, Balkau B, Coppack SW et al (2004) The EGIR-RISC STUDY (The European group for the study of insulin resistance: relationship between insulin sensitivity and cardiovascular disease risk): I. Methodology and objectives. Diabetologia 47:566–570CrossRefPubMed
22.
go back to reference Ferrannini E, Balkau B, Coppack SW et al (2007) Insulin resistance, insulin response, and obesity as indicators of metabolic risk. J Clin Endocrinol Metab 92:2885–2892CrossRefPubMed Ferrannini E, Balkau B, Coppack SW et al (2007) Insulin resistance, insulin response, and obesity as indicators of metabolic risk. J Clin Endocrinol Metab 92:2885–2892CrossRefPubMed
23.
go back to reference Mari A, Tura A, Gastaldelli A, Ferrannini E (2002) Assessing insulin secretion by modeling in multiple-meal tests: role of potentiation. Diabetes 51(Suppl 1):S221–S226CrossRefPubMed Mari A, Tura A, Gastaldelli A, Ferrannini E (2002) Assessing insulin secretion by modeling in multiple-meal tests: role of potentiation. Diabetes 51(Suppl 1):S221–S226CrossRefPubMed
24.
go back to reference Mari A, Schmitz O, Gastaldelli A, Oestergaard T, Nyholm B, Ferrannini E (2002) Meal and oral glucose tests for assessment of beta-cell function: modeling analysis in normal subjects. Am J Physiol Endocrinol Metab 283:E1159–E1166CrossRefPubMed Mari A, Schmitz O, Gastaldelli A, Oestergaard T, Nyholm B, Ferrannini E (2002) Meal and oral glucose tests for assessment of beta-cell function: modeling analysis in normal subjects. Am J Physiol Endocrinol Metab 283:E1159–E1166CrossRefPubMed
25.
go back to reference Mari A, Ferrannini E (2008) Beta-cell function assessment from modelling of oral tests: an effective approach. Diabetes Obes Metab 10(Suppl 4):S77–S87CrossRef Mari A, Ferrannini E (2008) Beta-cell function assessment from modelling of oral tests: an effective approach. Diabetes Obes Metab 10(Suppl 4):S77–S87CrossRef
26.
go back to reference Van Cauter E, Mestrez F, Sturis J, Polonsky KS (1992) Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 41:368–377CrossRefPubMed Van Cauter E, Mestrez F, Sturis J, Polonsky KS (1992) Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 41:368–377CrossRefPubMed
27.
go back to reference Stefanovski D, Richey JM, Woolcott O et al (2011) Consistency of the disposition index in the face of diet induced insulin resistance: potential role of FFA. PLoS One 6:e18134PubMedCentralCrossRefPubMed Stefanovski D, Richey JM, Woolcott O et al (2011) Consistency of the disposition index in the face of diet induced insulin resistance: potential role of FFA. PLoS One 6:e18134PubMedCentralCrossRefPubMed
28.
go back to reference Groop LC, Saloranta C, Shank M, Bonadonna RC, Ferrannini E, DeFronzo RA (1991) The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 72:96–107CrossRefPubMed Groop LC, Saloranta C, Shank M, Bonadonna RC, Ferrannini E, DeFronzo RA (1991) The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 72:96–107CrossRefPubMed
29.
go back to reference Groop LC, Bonadonna RC, DelPrato S et al (1989) Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest 84:205–213PubMedCentralCrossRefPubMed Groop LC, Bonadonna RC, DelPrato S et al (1989) Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest 84:205–213PubMedCentralCrossRefPubMed
30.
go back to reference Santomauro AT, Boden G, Silva ME et al (1999) Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes 48:1836–1841CrossRefPubMed Santomauro AT, Boden G, Silva ME et al (1999) Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes 48:1836–1841CrossRefPubMed
32.
go back to reference Dobbins RL, Chester MW, Daniels MB, McGarry JD, Stein DT (1998) Circulating fatty acids are essential for efficient glucose-stimulated insulin secretion after prolonged fasting in humans. Diabetes 7:1613–1618CrossRef Dobbins RL, Chester MW, Daniels MB, McGarry JD, Stein DT (1998) Circulating fatty acids are essential for efficient glucose-stimulated insulin secretion after prolonged fasting in humans. Diabetes 7:1613–1618CrossRef
33.
go back to reference Santini E, Fallahi P, Ferrari SM, Masoni A, Antonelli A, Ferrannini E (2004) Effect of PPAR-gamma activation and inhibition on glucose-stimulated insulin release in INS-1e cells. Diabetes 53(Suppl 3):S79–S83CrossRefPubMed Santini E, Fallahi P, Ferrari SM, Masoni A, Antonelli A, Ferrannini E (2004) Effect of PPAR-gamma activation and inhibition on glucose-stimulated insulin release in INS-1e cells. Diabetes 53(Suppl 3):S79–S83CrossRefPubMed
34.
go back to reference Hellmuth C, Demmelmair H, Schmitt I, Peissner W, Bluher M, Koletzko B (2013) Association between plasma nonesterified fatty acids species and adipose tissue fatty acid composition. PLoS One 8:e74927PubMedCentralCrossRefPubMed Hellmuth C, Demmelmair H, Schmitt I, Peissner W, Bluher M, Koletzko B (2013) Association between plasma nonesterified fatty acids species and adipose tissue fatty acid composition. PLoS One 8:e74927PubMedCentralCrossRefPubMed
35.
go back to reference Byrne CD, Maison P, Halsall D, Martensz N, Hales CN, Wareham NJ (1999) Cross-sectional but not longitudinal associations between non-esterified fatty acid levels and glucose intolerance and other features of the metabolic syndrome. Diabet Med 16:1007–1015CrossRefPubMed Byrne CD, Maison P, Halsall D, Martensz N, Hales CN, Wareham NJ (1999) Cross-sectional but not longitudinal associations between non-esterified fatty acid levels and glucose intolerance and other features of the metabolic syndrome. Diabet Med 16:1007–1015CrossRefPubMed
36.
go back to reference Salgin B, Ong KK, Thankamony A, Emmett P, Wareham NJ, Dunger DB (2012) Higher fasting plasma free fatty acid levels are associated with lower insulin secretion in children and adults and a higher incidence of type 2 diabetes. J Clin Endocrinol Metab 97:3302–3309CrossRefPubMed Salgin B, Ong KK, Thankamony A, Emmett P, Wareham NJ, Dunger DB (2012) Higher fasting plasma free fatty acid levels are associated with lower insulin secretion in children and adults and a higher incidence of type 2 diabetes. J Clin Endocrinol Metab 97:3302–3309CrossRefPubMed
37.
go back to reference Gillum MP, Zhang D, Zhang XM et al (2008) N-acylphosphatidylethanolamine, a gut- derived circulating factor induced by fat ingestion, inhibits food intake. Cell 135:813–824PubMedCentralCrossRefPubMed Gillum MP, Zhang D, Zhang XM et al (2008) N-acylphosphatidylethanolamine, a gut- derived circulating factor induced by fat ingestion, inhibits food intake. Cell 135:813–824PubMedCentralCrossRefPubMed
Metadata
Title
Influence of endogenous NEFA on beta cell function in humans
Authors
Eleni Rebelos
Marta Seghieri
Andrea Natali
Beverly Balkau
Alain Golay
Pier Marco Piatti
Nebojsa M. Lalic
Markku Laakso
Andrea Mari
Ele Ferrannini
Publication date
01-10-2015
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 10/2015
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-015-3685-6

Other articles of this Issue 10/2015

Diabetologia 10/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.